Affordable Access

deepdyve-link
Publisher Website

Prognostic Significance of the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Neuroendocrine Carcinoma

Authors
  • Kim, Hyeon-Jong1
  • Lee, Kang Han1
  • Shim, Hyun Jeong1
  • Hwang, Eu Chang1
  • Choi, Yoo-Duk1
  • Bang, Hyunjin1
  • Cho, Sang Hee1
  • Chung, Ik-Joo1, 1
  • Hwang, Jun Eul1
  • Lee, Myung Ah1
  • Bae, Woo Kyun1
  • 1 .
Type
Published Article
Journal
Chonnam Medical Journal
Publisher
Chonnam National University Medical School
Publication Date
Jan 25, 2022
Volume
58
Issue
1
Pages
29–36
Identifiers
DOI: 10.4068/cmj.2022.58.1.29
PMID: 35169557
PMCID: PMC8813653
Source
PubMed Central
Keywords
Disciplines
  • Original Article
License
Unknown

Abstract

Extra-pulmonary neuroendocrine carcinoma is a rare and aggressive cancer. Although several biological and histological markers have been suggested as prognostic factors for this cancer, the prognostic importance of systemic inflammatory markers, including the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio, is unclear. This study aimed to evaluate the association between systemic inflammatory markers and the prognosis of extra-pulmonary neuroendocrine carcinoma. We retrospectively analyzed the clinical data of 85 patients with unresectable or metastatic extra-pulmonary neuroendocrine carcinoma who received platinum-based chemotherapy as first-line chemotherapy from August 2007 to November 2019. We used time-dependent receiver operating characteristic curve analysis to determine the cut-off values. The cut-off values for the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio were 3.0 and 158.5, respectively. There was no significant difference in the Eastern Cooperative Oncology Group performance status score, Ki-67 index, or response to chemotherapy between groups. The high neutrophil-lymphocyte ratio group showed significantly worse overall survival (high vs. low, median 11.1 vs. 21.0 months, log-rank p=0.004) and shorter median progression-free survival, but the latter was not statistically significant. The high platelet-lymphocyte ratio group also showed significantly worse progression-free survival and overall survival than the low platelet-lymphocyte ratio group (high vs. low: median 5.6 vs. 9.8 months, log-rank p=0.047 and median 13.8 vs. 21.0 months, log-rank p=0.013, respectively). In multivariable analysis, a high neutrophil-lymphocyte ratio was an independent prognostic factor for overall survival. The neutrophil-lymphocyte ratio is a potent and readily available prognostic factor for extra-pulmonary neuroendocrine carcinoma.

Report this publication

Statistics

Seen <100 times